$JNJ RELEASED Q3 EARNINGS THIS MORNING: • Sales $25.40B vs Est. $25.38B (+5.9% YoY) • Adj. EPS $2.59 vs Est. $2.67 (-7.5% YoY) • GAAP EPS $0.09, hit by a one-time talc settlement charge plus the Firefly Bio and Sail deals • Innovative Medicine $16.76B (+7.7%), MedTech $8.64B (+2.5%) • Stelara a ~690bp drag. Growth driven by Tremfya, Darzalex, Carvykti, Rybrevant, Spravato, Caplyta FY26 Guidance: • Sales midpoint $101.2B vs Est. $101.34B (prior $101.1B) • Adj. EPS midpoint $11.10 vs Est. $11.29 (prior $11.04) Key quote (press release): "...increased sequential growth reflect the accelerating momentum of our focused portfolio... gives us clearer line of sight to double-digit growth by the end of the decade." Chairman & CEO Joaquin Duato